Skip to main content
. 2013 Sep 3;8(9):e74670. doi: 10.1371/journal.pone.0074670

Figure 3. Specific depletion of STAT3 sensitizes head and neck cancer cells to erlotinib.

Figure 3

A, STAT3 shRNA or control shRNA was transfected into Tu212 and Tu686 cells. Expression levels of STAT3, Bcl-XL and Bcl2 were analyzed by Western blot. B, Tu212 and Tu686 cells expressing STAT3 shRNA or control shRNA were treated with erlotinib (1µM) for 48h. Cell growth was determined by SRB assays.